MedTrace Logo

The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study

NCT02273895 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2014-10-24

No results posted yet for this study

Summary

The objective of this study is to compare the electroencephalography (EEG) responses of three distinct groups of individuals to scopolamine: 1) a group of Alzheimer Dementia (AD) patients, 2) a group of individuals suffering from Mild Cognitive Impairment (MCI) and 3) a group of controls. The main purpose of this comparison is to discover ways to use these responses to distinguish between the group of AD patients and controls in order to develop a diagnostic tool for AD. The purpose of including the MCI group is to investigate whether this diagnostic tool can predict which member of the MCI group will develop AD later in life.

Conditions

Interventions

DRUG

Scopolamine

0.3 mg/mL, intravenously, once

Sponsors & Collaborators

  • Landspitali University Hospital

    collaborator OTHER

  • Mentis Cura

    lead INDUSTRY

Principal Investigators

  • Jón Snædal, MD · Landspitali University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2004-10-31
Completion
2010-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02273895 on ClinicalTrials.gov